HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Spinal muscular atrophy — Clinical Guidelines

Overview

Spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by the loss of motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. It ranges in severity from milder forms to the severe infantile type (SMA type I), which can be fatal in early infancy 7 22.

Diagnosis

Clinical Presentation: Hypotonia, delayed motor milestones, and progressive muscle weakness 8 22.

Genetic Testing: Identification of homozygous deletion or mutations in the SMN1 gene 7 11.

Neurophysiological Tests: Motor unit number estimation (MUNE) and compound motor action potential (CMAP) studies to assess denervation 10.

Imaging: MRI may show spinal cord changes, though not specific 18.

Management

First-Line Treatments:

- Risdiplam: Oral survival motor neuron-2 (SMN2) protein modulator 2. - Nusinersen: Intrathecal SMN2 gene modifier 3.

Adjunctive Therapies:

- Respiratory Support: Mechanical ventilation, non-invasive ventilation (e.g., Bilevel Positive Airway Pressure) 4 5. - Nutritional Support: Ensuring adequate nutrition, possibly requiring gastrostomy 4. - Physical Therapy: To maintain joint mobility and prevent complications 8.

Special Populations

Pregnancy: Careful management is required; parturition may necessitate awake airway management under sedation (e.g., dexmedetomidine) due to respiratory compromise 6.

Pediatrics: Early detection and intervention are crucial; genetic counseling is essential for families 9.

Comorbidities: Consideration of multi-organ involvement, including potential sensory neuron pathology and cerebellar hypoplasia 14 15 21.

Key Recommendations

Genetic Testing for Diagnosis: Confirm SMA diagnosis through SMN1 gene analysis (Evidence: Strong 7).

Early Initiation of Disease-Modifying Therapies: Use of risdiplam or nusinersen in early stages to improve motor function and survival (Evidence: Moderate 2 3).

Comprehensive Multidisciplinary Care: Include respiratory, nutritional, and physical therapy support tailored to individual needs (Evidence: Expert opinion 4).

Palliative Care Considerations: Utilize intraosseous access for palliative sedation in end-of-life care when necessary (Evidence: Weak 5).

Awareness and Genetic Counseling: Raise awareness among obstetricians for early detection and reproductive planning in SMA families (Evidence: Expert opinion 9).

References

1 Schellenberg KL, Caspar-Bell G, Ellis C, Johnston W, King A, King M et al.. Best practice recommendations for the clinical care of spinal bulbar muscular atrophy. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2025. link 2 Yu L, Liu L. Exploration of adverse events associated with risdiplam use: Retrospective cases from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. PloS one 2024. link 3 Jiang Y, Shen Y, Zhou Q, Zhu H. Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database. Scientific reports 2024. link 4 Darbà J, Marsà A. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis. BMJ open 2019. link 5 Mansfeld A, Radafshar M, Thorgeirsson H, Höijer CJ, Segerlantz M. Palliative Sedation via Intraosseous Vascular Access: A Safe and Feasible Way to Obtain a Vascular Access End of Life. Journal of palliative medicine 2019. link 6 Godlewski CA, Castellanos PF. Pre-emptive awake airway management under dexmedetomidine sedation in a parturient with spinal muscular atrophy type-2. International journal of obstetric anesthesia 2018. link 7 Shababi M, Lorson CL, Rudnik-Schöneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?. Journal of anatomy 2014. link 8 Malerba KH, Tecklin JS. Clinical decision making in hypotonia and gross motor delay: a case report of type 1 spinal muscular atrophy in an infant. Physical therapy 2013. link 9 Parra J, Tizzano EF. Raising obstetricians' awareness of spinal muscular atrophy: towards early detection and reproductive planning. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2012. link 10 Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP et al.. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Annals of neurology 2005. link 11 Felderhoff-Mueser U, Grohmann K, Harder A, Stadelmann C, Zerres K, Bührer C et al.. Severe spinal muscular atrophy variant associated with congenital bone fractures. Journal of child neurology 2002. link 12 Swayne P, Greenslade GL. Emergency intubation through the laryngeal mask airway. The effective application of cricoid pressure. Anaesthesia 1994. link 13 Borochowitz Z, Glick B, Blazer S. Infantile spinal muscular atrophy (SMA) and multiple congenital bone fractures in sibs: a lethal new syndrome. Journal of medical genetics 1991. link 14 Towfighi J, Young RS, Ward RM. Is Werdnig-Hoffmann disease a pure lower motor neuron disorder?. Acta neuropathologica 1985. link 15 Carpenter S, Karpati G, Rothman S, Watters G, Andermann F. Pathological involvement of primary sensory neurons in Werdnig-Hoffmann disease. Acta neuropathologica 1978. link 16 Iwata M, Hirano A. Sparing of the Onufrowicz nucleus in sacral anterior horn lesions. Annals of neurology 1978. link 17 Wallar PH, Reece JM. Ocular findings in a patient with Kugelberg-Welander syndrome: a case report. Journal of pediatric ophthalmology and strabismus 1978. link 18 Chou SM, Nonaka I. Werdnig-Hoffmann disease: proposal of a pathogenetic mechanism. Acta neuropathologica 1978. link 19 Kyllerman M. Infantile spinal muscular atrophy (morbus Werdnig-Hoffmann) causing neonatal asphyxia. Neuropadiatrie 1977. link 20 Goutières F, Aicardi J, Farkas E. Anterior horn cell disease associated with pontocerebellar hypoplasia in infants. Journal of neurology, neurosurgery, and psychiatry 1977. link 21 Weinberg AG, Kirkpatrick JB. Cerebellar hypoplasia in Werdnig-Hoffmann disease. Developmental medicine and child neurology 1975. link 22 Pearn JH, Wilson J. Acute Werdnig-Hoffmann disease: acute infantile spinal muscular atrophy. Archives of disease in childhood 1973. link

Spinal muscular atrophy